Rebecca Cook
Faculty Member
Last active: 4/15/2019

  1. Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1. Werfel TA, Elion DL, Rahman B, Hicks DJ, Sanchez V, Gonzales-Ericsson PI, Nixon MJ, James JL, Balko JM, Scherle PA, Koblish HK, Cook RS (2019) Cancer Res 79(1): 171-182
    › Primary publication · 30413412 (PubMed)
  2. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. Lee T, Christov PP, Shaw S, Tarr JC, Zhao B, Veerasamy N, Jeon KO, Mills JJ, Bian Z, Sensintaffar JL, Arnold AL, Fogarty SA, Perry E, Ramsey HE, Cook RS, Hollingshead M, Davis Millin M, Lee KM, Koss B, Budhraja A, Opferman JT, Kim K, Arteaga CL, Moore WJ, Olejniczak ET, Savona MR, Fesik SW (2019) J Med Chem 62(8): 3971-3988
    › Primary publication · 30929420 (PubMed)
  3. Biological Consequences of MHC-II Expression by Tumor Cells in Cancer. Axelrod ML, Cook RS, Johnson DB, Balko JM (2019) Clin Cancer Res 25(8): 2392-2402
    › Primary publication · 30463850 (PubMed) · PMC6467754 (PubMed Central)
  4. Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers. Elion DL, Jacobson ME, Hicks DJ, Rahman B, Sanchez V, Gonzales-Ericsson PI, Fedorova O, Pyle AM, Wilson JT, Cook RS (2018) Cancer Res 78(21): 6183-6195
    › Primary publication · 30224377 (PubMed)
  5. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. Werfel TA, Wang S, Jackson MA, Kavanaugh TE, Joly MM, Lee LH, Hicks DJ, Sanchez V, Ericsson PG, Kilchrist KV, Dimobi SC, Sarett SM, Brantley-Sieders DM, Cook RS, Duvall CL (2018) Cancer Res 78(7): 1845-1858
    › Primary publication · 29358172 (PubMed) · PMC5882532 (PubMed Central)
  6. p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. Santos Guasch GL, Beeler JS, Marshall CB, Shaver TM, Sheng Q, Johnson KN, Boyd KL, Venters BJ, Cook RS, Pietenpol JA (2018) iScience : 236-249
    › Primary publication · 30340069 (PubMed) · PMC6197761 (PubMed Central)
  7. Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RS (2018) Target Oncol 13(1): 61-68
    › Primary publication · 29218624 (PubMed) · PMC5826865 (PubMed Central)
  8. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JM (2018) Oncoimmunology 7(6): e1438106
    › Primary publication · 29872580 (PubMed) · PMC5975601 (PubMed Central)
  9. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Williams MM, Lee L, Werfel T, Joly MMM, Hicks DJ, Rahman B, Elion D, McKernan C, Sanchez V, Estrada MV, Massarweh S, Elledge R, Duvall C, Cook RS (2018) Cell Death Dis 9(2): 21
    › Primary publication · 29343814 (PubMed) · PMC5833697 (PubMed Central)
  10. Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Elion DL, Cook RS (2018) Oncotarget 9(48): 29007-29017
    › Primary publication · 29989043 (PubMed) · PMC6034747 (PubMed Central)